Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis

Journal of Neuro-Oncology

Volumn 122, Issue 2, 2015, Pages 367-382

  Chowdhary, Sajeel A ^a   Ryken, Timothy ^b   Newton, Herbert B ^c  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b Iowa Spine and Brain Institute ^*  (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

BCNU; Carmustine; Gliadel; Glioblastoma; Glioma; High grade; Meta analysis; Wafer

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CARMUSTINE, POLIFERPROSAN 20 DRUG COMBINATION; DECANOIC ACID DERIVATIVE; DRUG IMPLANT; POLYESTER;

ADVERSE EFFECTS; BRAIN NEOPLASMS; CANCER GRADING; DRUG IMPLANT; GLIOMA; HUMAN; META ANALYSIS; PATHOLOGY; SURVIVAL; THERAPEUTIC USE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; DECANOIC ACIDS; DRUG IMPLANTS; GLIOMA; HUMANS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; POLYESTERS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84936882974     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1724-2     Document Type: Article

References (84)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14(Suppl 5):v1–v49
2. ®): central nervous system cancers, version 2.2013. National Comprehensive Cancer Network, Fort Washington, PA
3. Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190–v193
4. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198
5. Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A, Pedretti M, Polivka M, Xuan KH, Thillet J, Delattre JY, Sanson M (2006) Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107(8):1891–1897
6. 6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115(20):4783–4794
7. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115(15):3512–3518
8. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93(16):1246–1256
9. Cheng HB, Yue W, Xie C, Zhang RY, Hu SS, Wang Z (2013) IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis. Tumour Biol 34(6):3555–3559
10. ® wafer (polifeprosan 20 with carmustine implant) [prescribing information]. Eisai Inc., Woodcliff Lake, New Jersey
11. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41(1):44–48
12. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5(2):79–88
13. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 345(8956):1008–1012
14. Sabel M, Giese A (2008) Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 24(11):3239–3257
15. Fadul CE, Wen PY, Kim L, Olson JJ (2008) Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol 89(3):339–357
16. ®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg 25(4):459–469
17. Kleinberg L (2012) Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide. Core Evid 7:115–130
18. Affronti ML, Heery CR, Herndon JE, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS (2009) Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115(15):3501–3511
19. Anderson IA, Thomson S (2011) Complications following Gliadel wafer insertion during surgery for glioblastoma multiforme; a single centre-experience. Neuro Oncol 13(Suppl 2):ii1 (Abstract)
20. Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi JI, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M (2014) A multicenter phase I/II study of the BCNU implant (Gliadel wafer) for Japanese patients with malignant gliomas. Neurol Med Chir (Tokyo) 54(4):290–301
21. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15(10):2887–2893
22. Barr JG, Grundy PL (2012) The effects of the NICE Technology Appraisal 121 (Gliadel and temozolomide) on survival in high-grade glioma. Br J Neurosurg 26(6):818–822
23. Bock HC, Puchner MJ, Lohmann F, Schutze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A (2010) First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 33(4):441–449
24. Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74(3):441–446
25. Catalan-Uribarrena G, Bilbao-Barandica G, Pomposo-Gaztelu I, Undabeitia-Huertas J, Ruiz de Gopegui-Ruiz E, Galbarriatu-Gutierrez L, Canales-Llantada M, Aurrecoechea-Obieta J, Igartua-Azkune A, Carbayo-Lozano G (2012) Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. Acta Neurochir 154(2):211–222
26. Chaichana KL, Zaidi H, Pendleton C, McGirt MJ, Grossman R, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H (2011) The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol Res 33(7):759–764
27. Damilakis K, Paleologos TS, Papanikolaou PG, Venetikidis A, Mallios G, Stamatopoulos G, Chatzidakis E, Fratzoglou M, Kyriakou T (2011) Carmustine wafers treatment for firstly diagnosed malignant gliomas: a study of 22 cases. Presented at: 14th European Congress of Neurosurgery, October 9–14, Rome, Italy
28. Darakchiev BJ, Albright RE, Breneman JC, Warnick RE (2008) Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 108(2):236–242
29. De Bonis P, Anile C, Pompucci A, Fiorentino A, Balducci M, Chiesa S, Maira G, Mangiola A (2012) Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir 154(8):1371–1378
30. Della Puppa A, Rossetto M, Ciccarino P, Del MG, Rotilio A, Manara R, Paola Gardiman M, Denaro L, d’Avella D, Scienza R (2010) The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series. Acta Neurochir 152(11):1923–1931
31. Della Puppa A, Denaro L, Rossetto M, Ciccarino P, Manara R, Lombardi G, Del Moro G, Rotilio A, d’Avella D, Scienza R (2011) Postoperative seizure in high grade glioma patients treated with BCNU wafers: a mono-institutional experience. J Neurooncol 105(2):275–280
32. De’Santi MS, Genovese M, Amoroso E, Manto A, Piucci B (2011) 5-ALA guided surgery plus carmustine wafer implant and the Stupp regimen (radiotherapy and temozolomide) for the treatment of glioblastoma multiforme. Chirurgia 24(6):353–356
33. Desjardins A, Peters KB, Herndon JE II, Bailey LA, Alderson LM, Ranjan T, Sampson JH, Friedman AH, Bigner DD, Friedman HS, Vredenburgh JJ (2012) Newly diagnosed glioblastoma treated with Gliadel® followed by radiation therapy (RT), temozolomide and bevacizumab, and post-RT bevacizumab and temozolomide: a phase II study. Neuro Oncol 14(Suppl 6):104 (Abstract)
34. ® implantation—incidence, therapeutic strategies, and outcome. J Clin Neurosci 18(3):347–351
35. Duntze J, Litre CF, Eap C, Theret E, Debreuve A, Jovenin N, Lechapt-Zalcman E, Metellus P, Colin P, Guillamo JS, Emery E, Menei P, Rousseaux P, Peruzzi P (2013) Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol 20(6):2065–2072
36. Giese A, Kucinski T, Knopp U, Goldbrunner R, Hamel W, Mehdorn HM, Tonn JC, Hilt D, Westphal M (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66(3):351–360
37. Gutenberg A, Bock HC, Bruck W, Doerner L, Mehdorn HM, Roggendorf W, Westphal M, Felsberg J, Reifenberger G, Giese A (2013) MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. Br J Neurosurg 27(6):772–778
38. Ho J, Bruch J, Watts C, Price SJ (2011) The use of intra-operative carmustine chemotherapy wafers in the management of high grade gliomas: an assessment of complications and access to further therapy. Br J Neurosurg 25(2):163 (Abstract)
39. Hoffmann D (2009) Should Gliadel be mandatory in first intention operative treatment of high grade glioma? Presented at the Marseille Neurosurgery EANS-SFNC 2009 Joint Annual Meeting, March 27–31, Marseille
40. Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, Olivi A, Wharam MD, Brem H (2004) Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 22(1):1–9
41. Ko AL, Fink KR, Stelzer KM, Silbergeld DL (2012) Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma. Surg Neurol Int 3:137
42. Krex D, Juratli T, Lindner C, Raue C, Schackert G (2011) Local therapy in recurrent glioblastoma. Neuro-Oncology 13(Suppl 3):iii158 (Abstract)
43. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12(8):871–881
44. 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 118(18):4545–4554
45. Lemcke J, Grawe A, Golz L, Meier U (2013) Benefits and risks of camustin wavers in the therapy of malign glioblastoma. Presented at the European Association of Neurosurgical Societies, November 11–14, Tel Aviv
46. Lopez MJ, Garcia del Busto N, Cuenca M, Quintana B, Antonino G, Agustin S (2012) Use of carmustine implant in glioblastoma multiforme. Int J Clin Pharm 34(1):240 (Abstract)
47. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quinones-Hinojosa A (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110(3):583–588
48. McGovern PC, Lautenbach E, Brennan PJ, Lustig RA, Fishman NO (2003) Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis 36(6):759–765
49. Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, Jacquet G, Guyotat J (2010) Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17(7):1740–1746
50. Metellus P, Nanni-Metellus I, Chinot O, Fina F, Fuentes S, Dufour H, Barrie M, L’Houcine O, Figarella-Branger D (2011) Prognostic significance of MGMT promoter methylation status in elderly patients with newly diagnosed glioblastoma treated with BCNU water implantation: a prospective patient cohort. Neuro Oncol 13(Suppl 3):56 (Abstract)
51. Miglierini P, Bouchekoua M, Rousseau B, Dam HP, Malhaire JP, Pradier O (2012) Impact of the per-operatory application of Gliadel wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin Neurol Neurosurg 114(9):1222–1225
52. Noel G, Schott R, Froelich S, Gaub MP, Boyer P, Fischer-Lokou D, Dufour P, Kehrli P, Maitrot D (2012) Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 82(2):749–755
53. Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 88(3):353–357
54. Pérez Gómez R, Villanueva Álvarez A, Herruzo Cabrera I, Fortes de La Torre I, García Sánchez L, Ramos Trujillo A, Márquez Márquez B (2013) First-line treatment of malignant glioma with carmustine implants. Seven years-results. Rep Pract Oncol Radiother 18:S190 (Abstract)
55. Qadri SRM, Nicholae L, Jenkinson MD, Brodbelt A (2011) Treatment of recurrent high grade gliomas with Gliadel wafers after completion of adjuvant chemo-radiotherapy—the Walton Centre experience. Presented at the EORTC-EANO conference 2011, March 25–26, Bucharest
56. Qadri SRM, Jenkinson MD, Brodbelt A (2011) Recurrent high grade glioma after local carmustine wafer implant into the tumour bed. Does residual tumour affect progression? Br J Neurosurg 25(5):555 (Abstract)
57. 6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 15(3):1064–1068
58. Quiros J (2010) Radiotherapy with concomitant and adyuvant temozolomide with or without carmustune wafers in high grade glioma. Radiother Oncol 96:S269 (Abstract)
59. Ranjan T, Peters KB, Vlahovic G, Alderson LM, Herndon JE, McShery F, Threatt S, Sampson JH, Friedman AH, Bigner DD, Friedman HS, Vredenburgh JJ, Desjardins A (2013) Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT. J Clin Oncol 31(15 suppl):e13015 (Abstract)
60. Rezazadeh A, LaRocca RV, Vitaz TW, Villanueva WG, Hodes J, Haysley L (2011) A phase II study of multimodal therapy employing surgery, carmustine (BCNU) wafer, concomitant temozolomide and radiation, followed by dose dense therapy with temozolomide plus bevacizumab for newly diagnosed glioblastoma (GBM). Neuro Oncol 13(Suppl 3):iii90 (Abstract)
61. Ryken T (2011) Prospective multimodality therapy for newly diagnosed glioblastoma with surgical resection, implantable BCNU chemotherapy and combination radiotherapy and temozolomide: long-term follow-up. Neuro Oncol 13(Suppl 3):iii85 (Abstract)
62. Salmaggi A, Milanesi I, Silvani A, Gaviani P, Marchetti M, Fariselli L, Solero CL, Maccagnano C, Casali C, Guzzetti S, Pollo B, Ciusani E, DiMeco F (2013) Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J Neurosurg 118(4):821–829
63. Salvati M, D’elia A, Frati A, Brogna C, Santoro A, Delfini R (2011) Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. J Neurosurg Sci 55(1):1–6
64. Samis Zella MA, Wallocha M, Slotty PJ, Isik G, Hanggi D, Schroeteler J, Ewelt C, Steiger HJ, Sabel M (2014) Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. Acta Neurochir 156(2):313–323
65. Satilmis G, Samis Zella MA, Wallocha M, Schroeteler J, Steiger HJ, Sabel MC (2012) Evaluation of complications of carmustine wafer implantation in recurrent GBM. Presented at: 63rd annual meeting of the German Society of Neurosurgery Joint Meeting with the Japanese Neurosurgical Society, June 13–16, Leipzig
66. Shah RS, Homapour B, Casselden E, Barr JG, Grundy PL, Brydon HL (2014) Delayed post-operative haemorrhage after carmustine wafer implantation: a case series from two UK centres. Br J Neurosurg 28(4):488–494
67. Silvani A, Gaviani P, Lamperti E, Botturi A, DiMeco F, Broggi G, Fariselli L, Solero CL, Salmaggi A (2011) Phase II study: carmustine implant (Gliadel wafer) plus adjuvant and concomitant temozolomide in combination with radiotherapy in primary glioblastoma patients. Neuro Oncol 13(Suppl 3):iii46 Abstract
68. Smith KA, Ashby LS, Gonzalez LF, Brachman DG, Thomas T, Coons SW, Battaglia M, Scheck A (2008) Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg 109(Suppl 6):106–117
69. Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 45(1):17–22
70. ® wafer placement in patients with newly diagnosed high-grade gliomas: final results of a prospective, multi-institutional, phase I/II trial. Neuro Oncol 14(Suppl 6):vi66 (Abstract)
71. ® wafers in recurrent high grade glioma. Br J Neurosurg 23(5):482 (Abstract)
72. Ulmer S, Spalek K, Nabavi A, Schultka S, Mehdorn HM, Kesari S, Dorner L (2012) Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro Oncol 14(4):482–490
73. Watts C, Wanek K, Counsell N, Smith P (2013) Preliminary results of the GALA-5 study: an evaluation of the tolerability and feasibility of combining 5-amino-levulinic acid (5-ALA) with carmustine wafers (Gliadel) in the surgical management of primary glioblastoma. Presented at the NCRI cancer conference, November 3–6, Liverpool
74. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E (2006) Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir 148(3):269–275
75. Zhu JJ, Esquenazi-Levy Y, Friedman ER, Tandon N (2012) Retrospective review of 57 cases of glioblastoma treated with surgery and implantable BCNU wafer placement. Neuro Oncol 14(Suppl 6):vi60 (Abstract)
76. Gutenberg A, Lumenta CB, Braunsdorf WE, Sabel M, Mehdorn HM, Westphal M, Giese A (2013) The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas: a comprehensive review of the rationale and clinical experience. J Neurooncol 113(2):163–174
77. Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, Colman H, Chakravarti A, Jeraj R, Armstrong TS, Wefel JS, Brown PD, Jaeckle KA, Schiff D, Atkins JN, Brachman DG, Werner-Wasik M, Komaki R, Sulman EP, Mehta MP (2013) Phase III double-blind placebo-controlled trial evaluating bevacizumab (bev) in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 31(18 Suppl):1 (Abstract)
78. Wick W, Cloughsey TF, Nishikawa R, Mason W, Saran F, Henriksson R, Hilton M, Kerloeguen Y, Chinot OL (2013) Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma. J Clin Oncol 31(18 Suppl):2002 (Abstract)
79. La Rocca RV, Rezazadeh A (2011) Carmustine-impregnated wafers and their impact in the management of high-grade glioma. Expert Opin Pharmacother 12(8):1325–1332
80. Nagpal S (2012) The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma. Neurosurg Clin N Am 23(2):289–295
81. Perry J, Chambers A, Spithoff K, Laperriere N (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 14(5):189–194
82. Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K (2007) The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 11(45):iii–iv
83. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K (2011) Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. doi:10.1002/14651858.CD007294.pub2
84. Bregy A, Shah AH, Diaz MV, Pierce HE, Ames PL, Diaz D, Komotar RJ (2013) The role of Gliadel wafers in the treatment of high-grade gliomas. Exp Rev Anticancer Ther 13(12):1453–1461